GLP-1 Agonist Comparison 2026: Semaglutide vs Tirzepatide vs Retatrutide vs Orforglipron

The incretin-based therapeutics field has undergone rapid evolution since the approval of exenatide in 2005. By 2026, the landscape includes selective GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists, triple receptor agonists targeting GLP-1/GIP/glucagon receptors simultaneously, and the first non-peptide oral small-molecule GLP-1 agonist. Each generation represents a distinct approach to modulating incretin physiology, with differences in receptor selectivity, pharmacokinetic profile, route of administration, and clinical efficacy.

This comparison focuses on four compounds that define the current state of the field: semaglutide (the established benchmark), tirzepatide (the dual-agonist leader), retatrutide (the triple-agonist frontier), and orforglipron (the oral non-peptide breakthrough). Each compound is evaluated on its chemical properties, receptor pharmacology, and published clinical data.

Semaglutide is a modified human GLP-1 analog with a molecular weight of 4113.58 Da. It contains 31 amino acids with two key modifications: an Aib substitution at position 8 (conferring DPP-IV resistance) and a C18 fatty diacid moiety attached via a linker to Lys26 (enabling albumin binding and extending the half-life to approximately 165 hours). It is marketed as Ozempic (injectable, diabetes), Wegovy (injectable, obesity), and Rybelsus (oral, with SNAC absorption enhancer).

Semaglutide is a selective GLP-1 receptor agonist with no significant activity at the GIP or glucagon receptors. In the STEP clinical trial program, weekly subcutaneous semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks in the STEP 1 trial. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease.

Tirzepatide is a 39-amino acid dual GLP-1/GIP receptor co-agonist with a molecular weight of approximately 4813.45 Da. It is based on the native GIP sequence with modifications that enable cross-reactivity at the GLP-1 receptor, plus a C20 fatty diacid chain attached via a linker for albumin binding (half-life approximately 5 days). It is marketed as Mounjaro (diabetes) and Zepbound (obesity) by Eli Lilly.

The dual-agonist mechanism distinguishes tirzepatide from pure GLP-1 RAs. GIP receptor activation in the context of GLP-1 co-agonism appears to enhance weight loss beyond what GLP-1 activation alone achieves. In the SURMOUNT-1 trial, tirzepatide 15 mg weekly produced mean weight loss of 22.5% at 72 weeks — significantly exceeding semaglutide results. The proposed mechanism involves GIP-mediated effects on adipose tissue metabolism and energy expenditure in addition to the appetite-suppressing effects of GLP-1.

Retatrutide (LY3437943) is Eli Lilly's investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It is a 39-amino acid peptide with a molecular weight of approximately 4500 Da, incorporating a C20 fatty acid for extended half-life. Retatrutide represents the next evolutionary step beyond dual agonism by adding glucagon receptor activity.

Glucagon receptor activation adds a thermogenic component to the metabolic effects of GLP-1 and GIP signaling. Glucagon increases hepatic glucose output, stimulates lipolysis, and increases energy expenditure. In the Phase 2 trial, retatrutide 12 mg weekly produced mean weight loss of 24.2% at 48 weeks, with the highest-dose group achieving 28.7% at the same timepoint in the TRIUMPH-4 Phase 3 trial. These are the largest weight reductions reported for any pharmacological agent in clinical trials.

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist with a molecular weight of 541.65 Da, developed by Eli Lilly. Unlike semaglutide, tirzepatide, and retatrutide (which are all peptide-based), orforglipron is a synthetic small molecule that binds to and activates the GLP-1 receptor. It was approved by the FDA in April 2026 as the first oral GLP-1 agonist that does not require absorption enhancers or food restrictions.

The small-molecule nature of orforglipron provides manufacturing advantages (conventional chemical synthesis rather than peptide synthesis), stability advantages (no cold chain required, room temperature storage), and formulation flexibility (simple oral tablet, no SNAC enhancer). In Phase 3 trials, oral orforglipron 36 mg daily produced mean weight loss of approximately 14.7% at 72 weeks — comparable to injectable semaglutide 2.4 mg. The compound represents a paradigm shift from peptide-based to small-molecule incretin therapeutics.

• Semaglutide: MW 4113.58 Da | Selective GLP-1 RA | Injectable (weekly) or oral (daily with SNAC) | Mean weight loss 14.9% (STEP 1) | FDA-approved 2021 (obesity)
• Tirzepatide: MW ~4813.45 Da | Dual GLP-1/GIP | Injectable (weekly) | Mean weight loss 22.5% (SURMOUNT-1) | FDA-approved 2023 (obesity)
• Retatrutide: MW ~4500 Da | Triple GLP-1/GIP/Glucagon | Injectable (weekly) | Mean weight loss 28.7% (TRIUMPH-4 Phase 3) | Phase 3 as of 2026
• Orforglipron: MW 541.65 Da | Selective GLP-1 (non-peptide) | Oral (daily, no food restriction) | Mean weight loss ~14.7% (Phase 3) | FDA-approved April 2026

The four compounds represent a spectrum from single-target to multi-target pharmacology. Semaglutide and orforglipron activate only the GLP-1 receptor, producing appetite suppression through hypothalamic signaling, delayed gastric emptying, and enhanced satiety. Tirzepatide adds GIP receptor activation, which appears to enhance adipose tissue metabolism and amplify weight loss beyond GLP-1 alone. Retatrutide further adds glucagon receptor activation, introducing thermogenic and lipolytic effects.

The progression from mono- to dual- to triple-agonism has produced progressively greater weight loss in clinical trials, though it also increases the complexity of the pharmacological response and the potential for off-target effects. Glucagon receptor activation, for example, raises theoretical concerns about hepatic glucose output — though clinical data from retatrutide trials show that the GLP-1 component effectively counterbalances this effect in the context of the triple agonist.

Semaglutide has the most extensive clinical dataset, including the STEP program (weight management), SUSTAIN program (type 2 diabetes), PIONEER program (oral semaglutide), and SELECT (cardiovascular outcomes). The SELECT trial established semaglutide as the first obesity drug to demonstrate cardiovascular risk reduction in a dedicated outcomes trial.

Tirzepatide data from SURMOUNT and SURPASS trials demonstrate superior weight loss and glycemic control compared to existing GLP-1 RAs. Retatrutide Phase 3 data (TRIUMPH program) shows the highest weight loss numbers ever recorded in pharmacotherapy trials. Orforglipron Phase 3 data demonstrates that a non-peptide oral molecule can achieve weight loss comparable to injectable semaglutide, potentially expanding patient access by removing injection barriers.

The GLP-1 field illustrates several important principles for peptide research. First, receptor selectivity profoundly influences biological outcomes — the progression from mono- to dual- to triple-agonism demonstrates that multi-target peptides can achieve effects unattainable by single-target compounds. Second, chemical modifications (fatty acid conjugation, unnatural amino acids, DPP-IV-resistant substitutions) are essential for converting short-acting natural peptides into therapeutically useful molecules.

Third, the approval of orforglipron signals that non-peptide small molecules can replicate peptide receptor pharmacology, potentially disrupting the peptide therapeutics market for some targets. For researchers, this means that the boundary between peptide and small-molecule pharmacology is becoming increasingly blurred, with implications for synthesis, formulation, and analytical methodology.

Which GLP-1 agonist produces the most weight loss? Based on published Phase 3 data, retatrutide (triple agonist) has produced the highest mean weight loss at 28.7% at 48 weeks. However, retatrutide is not yet FDA-approved and direct head-to-head comparisons between all four agents have not been completed.

Is orforglipron a peptide? No. Orforglipron is a non-peptide small-molecule compound with a molecular weight of 541.65 Da. It activates the GLP-1 receptor through the same binding site as peptide GLP-1 agonists but is structurally distinct from any naturally occurring peptide.